April Kelly Scott Salama

April Kelly Scott Salama
Associate Professor of Medicine

Current Appointments & Affiliations

Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2018
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2010

Contact Information

30 Duke Medicine Circle, 25177 Morris Bldg, Durham, NC 27710
DUMC 3198, Durham, NC 27710

Background
Education, Training, & Certifications
- Hematology/Oncology, The University of Chicago 2007 - 2010
- Internal Medicine, The University of Chicago 2004 - 2007
- M.D., University of North Carolina - Chapel Hill 2004
Duke Appointment History
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2013 - 2018
- Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2011 - 2013
- Instructor Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2010
Research
Selected Grants
External Relationships
- Array Biopharma Inc.
- Novartis
- Regeneron Pharmaceuticals
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Hu, Janice B., Surya Ravichandran, Christel Rushing, Georgia M. Beasley, Brent A. Hanks, Sin-Ho Jung, April K. S. Salama, Lisa Ho, and Paul J. Mosca. “Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma.” Anticancer Res 40, no. 9 (September 2020): 5245–54. https://doi.org/10.21873/anticanres.14528.
    Full Text Link to Item
  - Dalal, Nicole H., Fumiko Chino, Hannah Williamson, Georgia M. Beasley, April K. S. Salama, and Manisha Palta. “Mind the gap: Gendered publication trends in oncology.” Cancer 126, no. 12 (June 2020): 2859–65. https://doi.org/10.1002/cncr.32818.
    Full Text
  - Theivanthiran, Balamayoora, Kathy S. Evans, Nicholas C. DeVito, Michael Plebanek, Michael Sturdivant, Luke P. Wachsmuth, April Ks Salama, et al. “A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.” J Clin Invest 130, no. 5 (May 1, 2020): 2570–86. https://doi.org/10.1172/JCI133055.
    Full Text Link to Item
  - Kennedy, Lucy Boyce, and April K. S. Salama. “A review of cancer immunotherapy toxicity.” Ca Cancer J Clin 70, no. 2 (March 2020): 86–104. https://doi.org/10.3322/caac.21596.
    Full Text Link to Item
  - Rao, P Kumar, Christopher Barker, Daniel G. Coit, Richard W. Joseph, Miguel Materin, Ramesh Rengan, Jeffrey Sosman, et al. “NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019.” J Natl Compr Canc Netw 18, no. 2 (February 2020): 120–31. https://doi.org/10.6004/jnccn.2020.0007.
    Full Text Link to Item
  - Wierda, William G., John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 2 (February 2020): 185–217. https://doi.org/10.6004/jnccn.2020.0006.
    Full Text Link to Item
  - Sankey, Eric W., Vadim Tsvankin, Matthew M. Grabowski, Gautam Nayar, Kristen A. Batich, Aida Risman, Cosette D. Champion, April K. S. Salama, C Rory Goodwin, and Peter E. Fecci. “Operative and peri-operative considerations in the management of brain metastasis.” Cancer Med 8, no. 16 (November 2019): 6809–31. https://doi.org/10.1002/cam4.2577.
    Full Text Link to Item
  - Mowery, Yvonne M., Kirtesh Patel, Mudit Chowdhary, Christel N. Rushing, Kingshuk Roy Choudhury, Jared R. Lowe, Adam C. Olson, et al. “Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study.” Radiother Oncol 138 (September 2019): 114–20. https://doi.org/10.1016/j.radonc.2019.06.013.
    Full Text Link to Item
  - Amaria, Rodabe N., Alexander M. Menzies, Elizabeth M. Burton, Richard A. Scolyer, Michael T. Tetzlaff, Robert Antdbacka, Charlotte Ariyan, et al. “Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.” Lancet Oncol 20, no. 7 (July 2019): e378–89. https://doi.org/10.1016/S1470-2045(19)30332-8.
    Full Text Link to Item
  - Leaf, Rebecca Karp, Christopher Ferreri, Deepa Rangachari, James Mier, Wesley Witteles, George Ansstas, Theodora Anagnostou, et al. “Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.” Am J Hematol 94, no. 5 (May 2019): 563–74. https://doi.org/10.1002/ajh.25448.
    Full Text Link to Item
  - Coit, Daniel G., John A. Thompson, Mark R. Albertini, Christopher Barker, William E. Carson, Carlo Contreras, Gregory A. Daniels, et al. “Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 17, no. 4 (April 1, 2019): 367–402. https://doi.org/10.6004/jnccn.2019.0018.
    Full Text Link to Item
  - Ott, Patrick A., Anna C. Pavlick, Douglas B. Johnson, Lowell L. Hart, Jeffrey R. Infante, Jason J. Luke, Jose Lutzky, et al. “A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.” Cancer 125, no. 7 (April 1, 2019): 1113–23. https://doi.org/10.1002/cncr.31892.
    Full Text Link to Item
  - Puza, Charles J., Elizabeth Schell Bressler, Alicia M. Terando, John Harrison Howard, Michael C. Brown, Brent Hanks, April K. S. Salama, and Georgia M. Beasley. “The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.” J Surg Res 236 (April 2019): 209–15. https://doi.org/10.1016/j.jss.2018.11.045.
    Full Text Link to Item
  - Kwak, Minyoung, Norma E. Farrow, April K. S. Salama, Paul J. Mosca, Brent A. Hanks, Craig L. Slingluff, and Georgia M. Beasley. “Updates in adjuvant systemic therapy for melanoma.” J Surg Oncol 119, no. 2 (January 2019): 222–31. https://doi.org/10.1002/jso.25298.
    Full Text Link to Item
  - Grant, Michael J., Nicholas DeVito, and April K. S. Salama. “Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations.” Melanoma Manag 5, no. 4 (December 2018): MMT10. https://doi.org/10.2217/mmt-2018-0004.
    Full Text Link to Item
  - Owonikoko, T. K., K. P. Papadopoulos, M. Gil-Martin, V. Moreno, A. K. Salama, E. Calvo, H. Safran, et al. “Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.” Ann Oncol 29 Suppl 8 (October 2018): viii461–62. https://doi.org/10.1093/annonc/mdy289.048.
    Full Text Link to Item
  - Ribas, A., I. Mehmi, T. Medina, C. Lao, S. Kummar, A. Amin, S. Deva, et al. “Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy.” Ann Oncol 29 Suppl 8 (October 2018): viii451–52. https://doi.org/10.1093/annonc/mdy289.021.
    Full Text Link to Item
  - Tan, Irena, Michael Malinzak, and April K. S. Salama. “Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.” J Immunother Cancer 6, no. 1 (July 31, 2018): 77. https://doi.org/10.1186/s40425-018-0390-2.
    Full Text Link to Item
  - Barker, Christopher A., and April K. Salama. “New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.” J Natl Compr Canc Netw 16, no. 5S (May 2018): 646–50. https://doi.org/10.6004/jnccn.2018.0042.
    Full Text Link to Item
  - Maio, Michele, Karl Lewis, Lev Demidov, Mario Mandalà, Igor Bondarenko, Paolo A. Ascierto, Christopher Herbert, et al. “Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.” Lancet Oncol 19, no. 4 (April 2018): 510–20. https://doi.org/10.1016/S1470-2045(18)30106-2.
    Full Text Link to Item
  - Bhatti, M. T., and A. K. S. Salama. “Neuro-ophthalmic side effects of molecularly targeted cancer drugs.” Eye (Lond) 32, no. 2 (February 2018): 287–301. https://doi.org/10.1038/eye.2017.222.
    Full Text Link to Item
  - Clarke, Jeffrey M., Daniel J. George, Stacey Lisi, and April K. S. Salama. “Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.” Target Oncol 13, no. 1 (February 2018): 1–20. https://doi.org/10.1007/s11523-017-0549-7.
    Full Text Link to Item
  - Hamid, Omid, Igor Puzanov, Reinhard Dummer, Jacob Schachter, Adil Daud, Dirk Schadendorf, Christian Blank, et al. “Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.” Eur J Cancer 86 (November 2017): 37–45. https://doi.org/10.1016/j.ejca.2017.07.022.
    Full Text Link to Item
  - Rossfeld, Kara, Erinn M. Hade, Alexandra Gangi, Matthew Perez, Emily N. Kinsey, Joanna Grabska, Ashley Ederle, et al. “Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics.” Int J Surg Oncol (N Y) 2, no. 9 (October 2017): e43. https://doi.org/10.1097/IJ9.0000000000000043.
    Full Text Link to Item
  - Beasley, Georgia M., Yinin Hu, Linda Youngwirth, Randall P. Scheri, April K. Salama, Kara Rossfeld, Syed Gardezi, et al. “Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study.” Ann Surg Oncol 24, no. 9 (September 2017): 2728–33. https://doi.org/10.1245/s10434-017-5883-6.
    Full Text Link to Item
  - Turner, Megan C., Kara Rossfeld, April K. S. Salama, Douglas Tyler, and Georgia Beasley. “Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?” Expert Opin Pharmacother 18, no. 5 (April 2017): 487–95. https://doi.org/10.1080/14656566.2017.1299710.
    Full Text Link to Item
  - Force, Jeremy, and April Ks Salama. “First-line treatment of metastatic melanoma: role of nivolumab.” Immunotargets Ther 6 (2017): 1–10. https://doi.org/10.2147/ITT.S110479.
    Full Text Open Access Copy Link to Item
  - Kinsey, E. N., and A. K. S. Salama. “Metastatic uveal melanoma-A review of current therapies and future directions.” European Oncology and Haematology 13, no. 2 (January 1, 2017): 100–106. https://doi.org/10.17925/OHR.2017.13.02.100.
    Full Text
  - Salama, A. K. S., and S. J. Moschos. “Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.” Ann Oncol 28, no. 1 (January 1, 2017): 57–74. https://doi.org/10.1093/annonc/mdw534.
    Full Text Link to Item
  - Salama, Atef Kamel. “Comparison between ketamine and hyoscine for the management of postoperative catheter-related bladder discomfort: A randomized controlled double-blind study.” J Anaesthesiol Clin Pharmacol 33, no. 1 (January 2017): 76–80. https://doi.org/10.4103/0970-9185.202191.
    Full Text Link to Item
  - Shoushtari, Alexander N., Rodrigo R. Munhoz, Deborah Kuk, Patrick A. Ott, Douglas B. Johnson, Katy K. Tsai, Suthee Rapisuwon, et al. “The efficacy of anti-PD-1 agents in acral and mucosal melanoma.” Cancer 122, no. 21 (November 15, 2016): 3354–62. https://doi.org/10.1002/cncr.30259.
    Full Text Link to Item
  - Hodi, F Stephen, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, et al. “Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.” Lancet Oncol 17, no. 11 (November 2016): 1558–68. https://doi.org/10.1016/S1470-2045(16)30366-7.
    Full Text Link to Item
  - Schadendorf, Dirk, Reinhard Dummer, Axel Hauschild, Caroline Robert, Omid Hamid, Adil Daud, Alfons van den Eertwegh, et al. “Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.” Eur J Cancer 67 (November 2016): 46–54. https://doi.org/10.1016/j.ejca.2016.07.018.
    Full Text Link to Item
  - Salama, A. K. S., and S. J. Moschos. “Next Steps in Immuno-Oncology: Enhancing Antitumor Effects Through Appropriate Patient Selection and Rationally Designed Combination Strategies.” Ann Oncol, October 13, 2016. https://doi.org/10.1093/annonc/mdw534.
    Full Text Link to Item
  - Choe, Jennifer H., Brian J. Andonian, Grace J. Kim, and April Ks Salama. “Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.” Immunotherapy 8, no. 10 (October 2016): 1163–67. https://doi.org/10.2217/imt-2016-0058.
    Full Text Link to Item
  - Hamid, O., I. Puzanov, R. Dummer, J. Schachter, A. Daud, D. Schadendorf, C. Blank, et al. “Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma.” Annals of Oncology 27 (October 1, 2016): vi379. https://doi.org/10.1093/annonc/mdw379.02.
    Full Text
  - Olson, Adam C., Samantha Thomas, Rosie Qin, Bhavana Singh, Joseph K. Salama, John Kirkpatrick, and April Ks Salama. “Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab.” Melanoma Manag 3, no. 3 (September 2016): 177–86. https://doi.org/10.2217/mmt-2016-0004.
    Full Text Link to Item
  - Qin, Rosie, Adam Olson, Bhavana Singh, Samantha Thomas, Steven Wolf, Nrupen A. Bhavsar, Brent A. Hanks, Joseph K. Salama, and April K. S. Salama. “Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab.” Int J Radiat Oncol Biol Phys 96, no. 1 (September 1, 2016): 72–77. https://doi.org/10.1016/j.ijrobp.2016.04.017.
    Full Text Link to Item
  - Sammons, Sarah, Donita Brady, Linda Vahdat, and April Ks Salama. “Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma.” Melanoma Manag 3, no. 3 (September 2016): 207–16. https://doi.org/10.2217/mmt-2015-0005.
    Full Text Link to Item
  - Coit, Daniel G., John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson, Gregory A. Daniels, et al. “NCCN Guidelines Insights: Melanoma, Version 3.2016.” J Natl Compr Canc Netw 14, no. 8 (August 2016): 945–58. https://doi.org/10.6004/jnccn.2016.0101.
    Full Text Link to Item
  - Farber, S Harrison, Vadim Tsvankin, Jessica L. Narloch, Grace J. Kim, April K. S. Salama, Gordana Vlahovic, Kimberly L. Blackwell, John P. Kirkpatrick, and Peter E. Fecci. “Embracing rejection: Immunologic trends in brain metastasis.” Oncoimmunology 5, no. 7 (July 2016): e1172153. https://doi.org/10.1080/2162402X.2016.1172153.
    Full Text Link to Item
  - Salama, April K. S., Michael A. Postow, and Joseph K. Salama. “Irradiation and immunotherapy: From concept to the clinic.” Cancer 122, no. 11 (June 1, 2016): 1659–71. https://doi.org/10.1002/cncr.29889.
    Full Text Link to Item
  - Brys, Adam K., Lubna Bhatti, Mustafa R. Bashir, Tracy A. Jaffe, Georgia M. Beasley, Neel S. Nath, April K. S. Salama, Douglas S. Tyler, and Paul J. Mosca. “Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma.” Ann Surg Oncol 23, no. 4 (April 2016): 1090–95. https://doi.org/10.1245/s10434-015-4972-7.
    Full Text Link to Item
  - Coit, Daniel G., John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson, Gregory A. Daniels, et al. “Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 14, no. 4 (April 2016): 450–73. https://doi.org/10.6004/jnccn.2016.0051.
    Full Text Link to Item
  - Barina, Andrew R., Mustafa R. Bashir, Brandon A. Howard, Brent A. Hanks, April K. Salama, and Tracy A. Jaffe. “Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis.” Abdom Radiol (Ny) 41, no. 2 (February 2016): 207–14. https://doi.org/10.1007/s00261-015-0560-3.
    Full Text Link to Item
  - Singh, Bhavana P., and April K. S. Salama. “Updates in Therapy for Advanced Melanoma.” Cancers (Basel) 8, no. 1 (January 15, 2016). https://doi.org/10.3390/cancers8010017.
    Full Text Link to Item
  - Amin, Asim, David H. Lawson, April K. S. Salama, Henry B. Koon, Troy Guthrie, Sajeve S. Thomas, Steven J. O’Day, et al. “Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.” J Immunother Cancer 4 (2016): 44. https://doi.org/10.1186/s40425-016-0148-7.
    Full Text Link to Item
  - Kinsey, E. N., N. DeVito, W. Barrow, S. A. Myers, and A. K. S. Salama. “Paraneoplastic Production of Granulocyte-macrophage Colony-stimulating Factor and Granulocyte Colony-stimulating Factor in a Case of Rapidly Progressing Cutaneous Squamous Cell Carcinoma.” Clinical Skin Cancer 1, no. 1 (January 1, 2016): 20–22. https://doi.org/10.1016/j.clsc.2016.11.004.
    Full Text
  - Lovly, Christine M., April K. S. Salama, and Ravi Salgia. “Tumor Heterogeneity and Therapeutic Resistance.” Am Soc Clin Oncol Educ Book 35 (2016): e585–93. https://doi.org/10.1200/EDBK_158808.
    Full Text Link to Item
  - Lowe, Jared R., Daniel J. Perry, April K. S. Salama, Clayton E. Mathews, Larry G. Moss, and Brent A. Hanks. “Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.” J Immunother Cancer 4 (2016): 89. https://doi.org/10.1186/s40425-016-0196-z.
    Full Text Open Access Copy Link to Item
  - Romain, P. E. S., A. K. S. Salama, N. Lynn Ferguson, and R. A. Burbridge. “Ipilimumab-Associated lymphocytic colitis: A case report.” Translational Gastroenterology and Hepatology 5, no. 1 (January 1, 2016): 44–46. https://doi.org/10.3978/j.issn.2224-4778.2015.10.11.
    Full Text
  - Salama, Ahmed K., Khaled A. Osman, and Neama Abdel-Razeek Gouda. “Remediation of lead and cadmium-contaminated soils.” Int J Phytoremediation 18, no. 4 (2016): 364–67. https://doi.org/10.1080/15226514.2015.1109597.
    Full Text Link to Item
  - Salama, Atef Kamal, and Hassan Mohamed Ali. “Comparative study of hyoscine doses as antisialagogue for patients receiving ketofol sedation undergoing colonoscopy procedures.” Anesth Essays Res 10, no. 1 (January 2016): 94–97. https://doi.org/10.4103/0259-1162.164735.
    Full Text Link to Item
  - Howie, Lynn J., Douglas S. Tyler, and April K. S. Salama. “Neoadjuvant use of ipilimumab in locally advanced melanoma.” J Surg Oncol 112, no. 8 (December 2015): 841–43. https://doi.org/10.1002/jso.24079.
    Full Text Link to Item
  - Qin, Rosie, and April Ks Salama. “Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus.” Melanoma Manag 2, no. 4 (November 2015): 311–14. https://doi.org/10.2217/mmt.15.27.
    Full Text Link to Item
  - Salama, Ahmed K. “Assessment of metals in cosmetics commonly used in Saudi Arabia.” Environ Monit Assess 188, no. 10 (October 2015): 553. https://doi.org/10.1007/s10661-016-5550-6.
    Full Text Link to Item
  - Ribas, Antoni, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F Stephen Hodi, et al. “Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.” Lancet Oncol 16, no. 8 (August 2015): 908–18. https://doi.org/10.1016/S1470-2045(15)00083-2.
    Full Text Link to Item
  - Postow, Michael A., Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth Grossmann, David McDermott, Gerald P. Linette, et al. “Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.” N Engl J Med 372, no. 21 (May 21, 2015): 2006–17. https://doi.org/10.1056/NEJMoa1414428.
    Full Text Link to Item
  - Dummer, R., A. Daud, I. Puzanov, O. Hamid, D. Schadendorf, C. Robert, J. Schachter, et al. “A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.” Journal of Translational Medicine, January 15, 2015, 1–2. https://doi.org/10.1186/1479-5876-13-S1-O5.
    Full Text
  - Bostwick, A Doran, April K. Salama, and Brent A. Hanks. “Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.” J Immunother Cancer 3 (2015): 19. https://doi.org/10.1186/s40425-015-0064-2.
    Full Text Open Access Copy Link to Item
  - Gangadhar, Tara C., and April Ks Salama. “Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types.” Onco Targets Ther 8 (2015): 929–37. https://doi.org/10.2147/OTT.S53164.
    Full Text Link to Item
  - Jiang, Betty S., Georgia M. Beasley, Paul J. Speicher, Paul J. Mosca, Michael A. Morse, Brent Hanks, April Salama, and Douglas S. Tyler. “Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.” Ann Surg Oncol 21, no. 8 (August 2014): 2525–31. https://doi.org/10.1245/s10434-014-3671-0.
    Full Text Link to Item
  - Coit, Daniel G., John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson, Gregory A. Daniels, et al. “Melanoma, version 4.2014.” J Natl Compr Canc Netw 12, no. 5 (May 2014): 621–29. https://doi.org/10.6004/jnccn.2014.0066.
    Full Text Link to Item
  - Beasley, Georgia M., Paul Speicher, Ketan Sharma, Hilliard Seigler, April Salama, Paul Mosca, and Douglas S. Tyler. “Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma.” J Am Coll Surg 218, no. 4 (April 2014): 686–92. https://doi.org/10.1016/j.jamcollsurg.2013.12.025.
    Full Text Link to Item
  - Salama, April K. S., and Kevin B. Kim. “MEK inhibition in the treatment of advanced melanoma.” Curr Oncol Rep 15, no. 5 (October 2013): 473–82. https://doi.org/10.1007/s11912-013-0336-2.
    Full Text Link to Item
  - Salama, April K. S., and Keith T. Flaherty. “BRAF in melanoma: current strategies and future directions.” Clin Cancer Res 19, no. 16 (August 15, 2013): 4326–34. https://doi.org/10.1158/1078-0432.CCR-13-0779.
    Full Text Link to Item
  - Salama, April K. S., and Kevin B. Kim. “Trametinib (GSK1120212) in the treatment of melanoma.” Expert Opin Pharmacother 14, no. 5 (April 2013): 619–27. https://doi.org/10.1517/14656566.2013.770475.
    Full Text Link to Item
  - Shetty, Gina, Georgia M. Beasley, Sara Sparks, Michael Barfield, Melanie Masoud, Paul J. Mosca, Scott K. Pruitt, et al. “Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.” Ann Surg Oncol 20, no. 4 (April 2013): 1128–35. https://doi.org/10.1245/s10434-012-2785-5.
    Full Text Link to Item
  - Salama, April K. S. “Evolving pharmacotherapies for the treatment of metastatic melanoma.” Clin Med Insights Oncol 7 (2013): 137–49. https://doi.org/10.4137/CMO.S9565.
    Full Text Link to Item
  - Salama, April K. S., Nicole de Rosa, Randall P. Scheri, Scott K. Pruitt, James E. Herndon, Jennifer Marcello, Douglas S. Tyler, and Amy P. Abernethy. “Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.” Plos One 8, no. 3 (2013): e57665. https://doi.org/10.1371/journal.pone.0057665.
    Full Text Open Access Copy Link to Item
  - Gajewski, Thomas F., April K. S. Salama, Donna Niedzwiecki, Jeffrey Johnson, Gerald Linette, Cynthia Bucher, Michelle A. Blaskovich, Said M. Sebti, Frank Haluska, and Frank Cancer and Leukemia Group B. “Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).” J Transl Med 10 (December 10, 2012): 246. https://doi.org/10.1186/1479-5876-10-246.
    Full Text Link to Item
  - Salama, April K. S., Nicole de Rosa, Randall P. Scheri, James E. Herndon, Douglas S. Tyler, Jennifer Marcello, Scott K. Pruitt, and Amy P. Abernethy. “The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost.” Cancer Invest 30, no. 9 (November 2012): 637–41. https://doi.org/10.3109/07357907.2012.726387.
    Full Text Link to Item
  - Beasley, Georgia M., Colin Parsons, Gloria Broadwater, M Angelica Selim, Suroosh Marzban, Amy P. Abernethy, April K. S. Salama, et al. “A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.” Ann Surg 256, no. 2 (August 2012): 350–56. https://doi.org/10.1097/SLA.0b013e318256d1f5.
    Full Text Link to Item
  - Salama, April K. S., and F Stephen Hodi. “Cytotoxic T-lymphocyte-associated antigen-4.” Clin Cancer Res 17, no. 14 (July 15, 2011): 4622–28. https://doi.org/10.1158/1078-0432.CCR-10-2232.
    Full Text Link to Item
  - Salgia, Ravi, Thomas Hensing, Nicholas Campbell, April K. Salama, Michael Maitland, Philip Hoffman, Victoria Villaflor, and Everett E. Vokes. “Personalized treatment of lung cancer.” Semin Oncol 38, no. 2 (April 2011): 274–83. https://doi.org/10.1053/j.seminoncol.2011.01.012.
    Full Text Link to Item
  - Mollberg, N., M. Surati, C. Demchuk, R. Fathi, A. K. Salama, A. N. Husain, T. Hensing, and R. Salgia. “Mind-mapping for lung cancer: towards a personalized therapeutics approach.” Adv Ther 28, no. 3 (March 2011): 173–94. https://doi.org/10.1007/s12325-010-0103-9.
    Full Text Link to Item
  - Surati, Mosmi, Matthew Robinson, Suvobroto Nandi, Leonardo Faoro, Carley Demchuk, Cleo E. Rolle, Rajani Kanteti, et al. “Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.” J Clin Bioinforma 1, no. 8 (February 28, 2011): 1–11. https://doi.org/10.1186/2043-9113-1-8.
    Full Text Link to Item
  - El-Gendy, Kawther S., Nagat M. Aly, Eman M. Mosallam, and Ahmed K. Salama. “Preparation of antibodies and development of an enzyme immunoassay for determination of atrazine in environmental samples.” J Environ Sci Health B 46, no. 4 (2011): 321–27. https://doi.org/10.1080/03601234.2011.559885.
    Full Text Link to Item
  - Tretiakova, Maria, April K. S. Salama, Theodore Karrison, Mark K. Ferguson, Aliya N. Husain, Everett E. Vokes, and Ravi Salgia. “MET and phosphorylated MET as potential biomarkers in lung cancer.” J Environ Pathol Toxicol Oncol 30, no. 4 (2011): 341–54. https://doi.org/10.1615/jenvironpatholtoxicoloncol.v30.i4.70.
    Full Text Link to Item
  - Scott, April, and Ravi Salgia. “Biomarkers in lung cancer: from early detection to novel therapeutics and decision making.” Biomarkers in Medicine 2, no. 6 (December 2008): 577–86. https://doi.org/10.2217/17520363.2.6.577.
    Full Text
  - Radwan, Mohamed A., and Ahmed K. Salama. “Market basket survey for some heavy metals in Egyptian fruits and vegetables.” Food Chem Toxicol 44, no. 8 (August 2006): 1273–78. https://doi.org/10.1016/j.fct.2006.02.004.
    Full Text Link to Item
  - Gangadhar, Tara C., Wen-Jen Hwu, Michael A. Postow, Omid Hamid, Adil Daud, Roxana Dronca, Richard Joseph, et al. “Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.” J Immunother 40, no. 9 (n.d.): 334–40. https://doi.org/10.1097/CJI.0000000000000186.
    Full Text Link to Item
- Book Sections
  - Sammons, S., M. McNamara, A. K. S. Salama, and J. Crawford. “Immune checkpoint inhibition.” In Side Effects of Medical Cancer Therapy: Prevention and Treatment: Second Edition, 315–53, 2018. https://doi.org/10.1007/978-3-319-70253-7_12.
    Full Text
- Conference Papers
  - Dalal, N. H., F. Chino, H. Williamson, G. Beasley, A. K. S. Salama, and M. Palta. “Mind the Gap: Gendered Publication Trends in Academic Oncology.” In International Journal of Radiation Oncology*Biology*Physics, 105:E146–E146. Elsevier BV, 2019. https://doi.org/10.1016/j.ijrobp.2019.06.2198.
    Full Text
  - Salama, April K. S., Shuli Li, Erin Renee Macrae, Jong-In Park, Edith P. Mitchell, James A. Zwiebel, Helen X. Chen, et al. “Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.” In Journal of Clinical Oncology, 37:3002–3002. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.3002.
    Full Text
  - Owonikoko, Taofeek Kunle, Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Marta Gil Martin, Victor Moreno, April K. S. Salama, Emiliano Calvo, et al. “Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.” In Journal of Clinical Oncology, 36:9557–9557. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.9557.
    Full Text
  - Ribas, Antoni, Mohammed M. Milhem, Christopher J. Hoimes, Asim Amin, Inderjit Mehmi, Christopher D. Lao, Robert Martin Conry, et al. “Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” In Journal of Clinical Oncology, 36:9513–9513. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.9513.
    Full Text
  - Patel, S. P., F. S. Hodi, D. Gabrilovich, M. Chin, G. Gibney, A. Goldsberry, R. Gonzalez, et al. “A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma.” In Annals of Oncology, 28:xi30, 2017. https://doi.org/10.1093/annonc/mdx760.
    Full Text
  - Theivanthiran, Bala, Nicholas C. DeVito, Kathy Evans, Fei Zhao, Christine Xiao, Benjamin S. Goldschmidt, Rob Edgar, et al. “A HSP-TLR-Wnt5a paracrine signaling axis drives CXCR2 ligand recruitment of myeloid-derived suppressor cells and represents a novel adaptive resistance mechanism to anti-PD-1 antibody therapy.” In Journal for Immunotherapy of Cancer, Vol. 5. BMC, 2017.
    Link to Item
  - Ott, P. A., A. C. Pavlick, D. B. Johnson, L. L. Hart, J. R. Infante, J. J. Luke, J. Lutzky, et al. “A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.” In Annals of Oncology, 27:vi393, 2016. https://doi.org/10.1093/annonc/mdw379.42.
    Full Text
  - Gajewski, T. F., D. Niedzwiecki, J. Johnson, G. Linette, C. Bucher, M. Blaskovich, S. Sebti, and F. Haluska. “Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104.” In Journal of Clinical Oncology, 24:456S-456S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Salama, April. “Characterizing Long-Term Outcomes in Metastatic Melanoma in 2020,” n.d.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Conference Papers